Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
The mechanistic target of rapamycin (mTOR) is an established therapeutic target in renal cell carcinoma (RCC). Mechanisms of secondary resistance to rapalog therapy in RCC have not been studied previously. We identified six patients with metastatic RCC who initially responded to mTOR inhibitor thera...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science (PLoS)
2018-09-01
|
| Colecção: | PLoS Genetics |
| Acesso em linha: | https://hdl.handle.net/10923/21647 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|